Plasmapheresis in neuroleptic malignant syndrome.
Neuroleptic malignant syndrome is a severe and potentially fatal reaction to neuroleptic drugs. Treatment requires withdrawal of the neuroleptic agent, metabolic and cardiovascular support, physical cooling and treatment with dantrolene sodium and bromcriptine mesylate. We report a therapeutic success of plasmapheresis in a case of neuroleptic malignant syndrome in which conventional therapy had failed. We postulate that plasmapheresis may prove to be a useful tool in treating this frequently fatal disease.
Gaitini
L
L
Department of Anesthesiology, Bnai-Zion Medical Center, Haifa, Israel.
Fradis
M
M
Vaida
S
S
Krimerman
S
S
Beny
A
A
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects; D001831:Body Temperature; D003402:Creatine Kinase / Q000097:blood; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology / Q000628:therapy*; D010956:Plasmapheresis
D014150:Antipsychotic Agents; D003402:Creatine Kinase; D006220:Haloperidol